146 related articles for article (PubMed ID: 38484234)
1. A Comparison of U.S. Individual and Family Plan Medication Coverage for Overactive Bladder.
Gaddam NG; Wallace MB; Dieter AA
Urogynecology (Phila); 2024 Mar; 30(3):214-222. PubMed ID: 38484234
[TBL] [Abstract][Full Text] [Related]
2. Impact of Overactive Bladder Step Therapy Policies on Medication Utilization and Expenditures Among Treated Medicare Members.
Abbass IM; Caplan EO; Ng DB; Kristy R; Schermer CR; Bradt P; Collins JM; Chan WM; Suehs BT
J Manag Care Spec Pharm; 2017 Jan; 23(1):27-37. PubMed ID: 28025920
[TBL] [Abstract][Full Text] [Related]
3. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.
Perk S; Wielage RC; Campbell NL; Klein TM; Perkins A; Posta LM; Yuran T; Klein RW; Ng DB
J Manag Care Spec Pharm; 2016 Sep; 22(9):1072-84. PubMed ID: 27579830
[TBL] [Abstract][Full Text] [Related]
4. [Assessment of prescribing practices in overactive bladder pharmacotherapy across different specialties of India: a prescription trend analysis].
Krunal Vishavadia KV; Sandip Solanki SS; Hiren Prajapati HP; Madhu Sharma MS
Urologiia; 2023 May; (2):66-72. PubMed ID: 37401707
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States.
Chen JV; Klein TM; Nesheim J; Mudd PN
J Med Econ; 2022; 25(1):1092-1100. PubMed ID: 35993729
[TBL] [Abstract][Full Text] [Related]
6. Which anticholinergic drug for overactive bladder symptoms in adults.
Madhuvrata P; Cody JD; Ellis G; Herbison GP; Hay-Smith EJ
Cochrane Database Syst Rev; 2012 Jan; 1():CD005429. PubMed ID: 22258963
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
Chapple CR; Cruz F; Cardozo L; Staskin D; Herschorn S; Choudhury N; Stoelzel M; Heesakkers J; Siddiqui E
Eur Urol; 2020 Jan; 77(1):119-128. PubMed ID: 31635815
[TBL] [Abstract][Full Text] [Related]
8. Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents.
Lua LL; Pathak P; Dandolu V
Neurourol Urodyn; 2017 Nov; 36(8):2123-2131. PubMed ID: 28467609
[TBL] [Abstract][Full Text] [Related]
9. Treatments for overactive bladder: focus on pharmacotherapy.
Geoffrion R;
J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
[TBL] [Abstract][Full Text] [Related]
10. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan.
D'Souza AO; Smith MJ; Miller LA; Doyle J; Ariely R
J Manag Care Pharm; 2008 Apr; 14(3):291-301. PubMed ID: 18439051
[TBL] [Abstract][Full Text] [Related]
11. Trends in the use of older overactive bladder agents and uptake of fesoterodine and mirabegron in Canada.
Minhas R; Tadrous M; Elterman D; Gomes T
Neurourol Urodyn; 2018 Jun; 37(5):1693-1700. PubMed ID: 29682790
[TBL] [Abstract][Full Text] [Related]
12. [Comprehensive pharmacologic management of overactive bladder].
Krivoborodov GG; Tur EI
Urologiia; 2017 Apr; (1):82-88. PubMed ID: 28394529
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison.
Maman K; Aballea S; Nazir J; Desroziers K; Neine ME; Siddiqui E; Odeyemi I; Hakimi Z
Eur Urol; 2014 Apr; 65(4):755-65. PubMed ID: 24275310
[TBL] [Abstract][Full Text] [Related]
14. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
[TBL] [Abstract][Full Text] [Related]
15. The cognitive effect of anticholinergics for patients with overactive bladder.
Welk B; Richardson K; Panicker JN
Nat Rev Urol; 2021 Nov; 18(11):686-700. PubMed ID: 34429535
[TBL] [Abstract][Full Text] [Related]
16. Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA.
Chen JV; Gahn JC; Nesheim J; Mudd PN
Pharmacoeconomics; 2022 Oct; 40(10):979-988. PubMed ID: 35881325
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.
Nazir J; Maman K; Neine ME; Briquet B; Odeyemi IA; Hakimi Z; Garnham A; Aballéa S
Value Health; 2015 Sep; 18(6):783-90. PubMed ID: 26409605
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Therapeutic Efficacy and Urodynamic Findings of Solifenacin Succinate versus Mirabegron in Women with Overactive Bladder Syndrome: Results of a Randomized Controlled Study.
Vecchioli Scaldazza C; Morosetti C
Urol Int; 2016; 97(3):325-329. PubMed ID: 27092789
[TBL] [Abstract][Full Text] [Related]
19. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A
Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
[TBL] [Abstract][Full Text] [Related]
20. A Nordic registry-based study of drug treatment patterns in overactive bladder patients.
Milsom I; Schiotz HA; Svensson M; Kilany S; Hansson F
Scand J Urol; 2019 Aug; 53(4):246-254. PubMed ID: 31195868
[No Abstract] [Full Text] [Related]
[Next] [New Search]
